The Preparation, Handling and Use of Intravesical Bacillus Calmette-Guerin for the Management of Stage Ta, T1, Carcinoma in Situ and Transitional Cell Cancer
- 1 August 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 144 (2 Part 1) , 313-315
- https://doi.org/10.1016/s0022-5347(17)39441-7
Abstract
The increasing use of bacillus Calmette-Guerin in the treatment of patients with low stage bladder cancer will inevitably bring attention to problems of proper use and toxicity. There is a need to identify patients who are most likely to benefit from this therapy and those who may be at risk for serious complications.This publication has 10 references indexed in Scilit:
- A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.Journal of Clinical Oncology, 1987
- Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder CancerJournal of Urology, 1987
- Two Courses of Intravesical Bacillus Calmette-Guerin for Transitional Cell Carcinoma of the BladderJournal of Urology, 1986
- Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder CancerJournal of Urology, 1986
- Long-Term Effect of Intravesical Bacillus Calmette-Guerin on Flat Carcinoma in Situ of the BladderJournal of Urology, 1986
- Immunotherapy of superficial bladder cancer with BCGWorld Journal of Urology, 1986
- Bacillus Calmette-Guerin Immunotherapy for Bladder CancerJournal of Urology, 1985
- Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1982
- BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responsesCancer, 1981
- Hazards and Complications of BCG ImmunotherapyMedical Clinics of North America, 1976